American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.
The informCLL registry of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) can help to resolve knowledge gaps that may be identified in the evaluation and treatment of patients with CLL/SLL. Read More ›

As salvage therapy in younger patients with relapsed/refractory acute myeloid leukemia (AML), the efficacy of 10-day decitabine + venetoclax is comparable to intensive chemotherapy regimens and is an appropriate bridge to allogeneic stem-cell transplantation. Read More ›

Primary results from the CAPTIVATE study demonstrate that fixed-duration treatment with ibrutinib plus venetoclax offers treatment-free remission for patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

Across multiple acute myeloid leukemia (AML) subgroups, venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile, representing an attractive option as a bridge to allo-SCT for adverse-risk, newly diagnosed, and relapsed/refractory (R/R) AML patients. Read More ›

Combination ibrutinib plus venetoclax treatment results in sustained response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). This response is sustained despite planned discontinuation in patients who had achieved minimal residual disease. Read More ›

In older patients with de novo acute myeloid leukemia, the combination of selinexor with standard induction and consolidation therapy appears highly active. Read More ›

Individual clonal growth rates can be used to estimate the minimal residual disease doubling time after fixed-duration treatment. Clonal growth rates were lower after treatment with venetoclax-obinutuzumab when compared with chlorambucil-obinutuzumab. Read More ›

In patients with newly diagnosed IDH2mut acute myeloid leukemia (AML), treatment with enasidenib was associated with low early death and high complete response and complete response with incomplete hematologic recovery rates and yielded durable remission. Read More ›

Updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the BCMA-directed CAR T-cell therapy, idecabtagene vicleucel, in RRMM at target dose levels of ≥150 × 106 CAR+ T-cells. Read More ›

The combination regimen of thalidomide, prednisone, and methotrexate demonstrated greater efficacy than treatment with cyclosporine and prednisone in patients with large granular lymphocytic leukemia and with limited adverse events. Read More ›

Page 10 of 44

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications